Iovance Biotherapeutics, Inc.
IOVANASDAQHealthcareBiotechnology
Previous close
$8.29
−$0.70 · -7.79%
IOVA company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Buy
Favorable setup — positive multi-factor alignment
Valuation
77
Undervalued
Momentum
66
Gaining
Sentiment
64
Bullish
Risk resilience
52
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteIovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Frederick G. Vogt
- Listed since
- Oct 15, 2010
- Employees
- 975
Market position
Day range
Current $8.29
52-week range
Current $8.29
- Open
- $9.08
- Previous close
- $8.99
- Volume
- 27.81M
- 1.72× average
- Average volume
- 16.18M
- Average daily volume
- Market cap
- 3.7B USD
- Beta
- 0.7
- Market reference 1
- 50-day average
- $5.0438
- +64.36% above average
- 200-day average
- $3.6269
- +128.57% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 860.92M USD
- P/E (TTM)
- -11.84×
- P/B (TTM)
- 5.07×
- P/S (TTM)
- 11.39×
- EV / EBITDA
- -2.41×
- Earnings yield
- -40.08%
- Free cash flow yield
- -34.47%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 116.30%
- Operating margin
- -92.72%
- Net margin
- -89.09%
- Return on equity
- -55.97%
- Return on assets
- -42.82%
- Return on invested capital
- -51.52%
Financial health
- Debt / equity
- 0.06×
- Current ratio
- 3.2×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 263.5M USD | 164.07M USD | 1.19M USD | — | — |
| Cost of goods sold | 7.29M USD | 124M USD | 10.76M USD | — | — |
| Gross profit | 256.22M USD | 40.08M USD | −9.57M USD | — | — |
| Research and development | 300.27M USD | 282.34M USD | 344.08M USD | 294.78M USD | 259.04M USD |
| Selling, general, and administrative | 152.32M USD | 153.02M USD | 106.92M USD | 104.1M USD | 83.66M USD |
| Operating expenses | 659.57M USD | 435.35M USD | 450.99M USD | 398.88M USD | 342.7M USD |
| Interest income | — | 20.27M USD | 13.04M USD | 2.99M USD | 451K USD |
| Interest expense | — | — | — | 2.99M USD | — |
| Depreciation and amortization | 35.94M USD | 43.61M USD | 33.13M USD | 21.14M USD | 13.98M USD |
| Operating income | −403.36M USD | −395.28M USD | −460.56M USD | −398.88M USD | −342.7M USD |
| Net income | −390.98M USD | −372.18M USD | −444.04M USD | −395.89M USD | −342.25M USD |
Company facts updated Aug 24, 2026.
IOVA peers
ETFs holding IOVA
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI136.77M1.20%11.39B USD0.35%$165.73+1.44%
iShares Russell 2000 ETFIWM91.64M0.11%81.62B USD0.19%$299.96+0.77%
Vanguard Morningstar Total Stock Market ETFVTI55.08M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 Value ETFIWN33.24M0.23%14.66B USD0.24%$224.81+0.45%
iShares Biotechnology ETFIBB26.11M0.25%10.75B USD0.44%$213.56+1.29%
Vanguard Morningstar Small-Cap ETFVB19.84M0.01%183.4B USD0.03%$304.76+0.64%
Vanguard Extended Market ETFVXF17.55M0.02%93.7B USD0.05%$245.53+0.82%
Schwab U.S. Small-Cap ETFSCHA16.2M0.07%23.1B USD0.03%$34.83+0.52%State Street SPDR S&P Biotech ETFXBI- Market value
- 136.77M
- Weight
- 1.20%
- AUM
- 11.39B USD
- Expense ratio
- 0.35%
- Price / 1D
- $165.73+1.44%
iShares Russell 2000 ETFIWM- Market value
- 91.64M
- Weight
- 0.11%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 55.08M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 Value ETFIWN- Market value
- 33.24M
- Weight
- 0.23%
- AUM
- 14.66B USD
- Expense ratio
- 0.24%
- Price / 1D
- $224.81+0.45%
iShares Biotechnology ETFIBB- Market value
- 26.11M
- Weight
- 0.25%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
Vanguard Morningstar Small-Cap ETFVB- Market value
- 19.84M
- Weight
- 0.01%
- AUM
- 183.4B USD
- Expense ratio
- 0.03%
- Price / 1D
- $304.76+0.64%
Vanguard Extended Market ETFVXF- Market value
- 17.55M
- Weight
- 0.02%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
Schwab U.S. Small-Cap ETFSCHA- Market value
- 16.2M
- Weight
- 0.07%
- AUM
- 23.1B USD
- Expense ratio
- 0.03%
- Price / 1D
- $34.83+0.52%
Continue in GoAI
Research IOVAresearch.disclaimer